LAG-3 regulates plasmacytoid dendritic cell homeostasis
- PMID: 19201841
- PMCID: PMC2675170
- DOI: 10.4049/jimmunol.0800185
LAG-3 regulates plasmacytoid dendritic cell homeostasis
Abstract
Lymphocyte activation gene 3 (LAG-3) is a CD4-related, activation-induced cell surface molecule expressed by various lymphoid cell types and binds to MHC class II with high affinity. We have previously shown that LAG-3 negatively regulates the expansion of activated T cells and T cell homeostasis, and is required for maximal regulatory T cell function. In this study, we demonstrate for the first time that LAG-3 is also expressed on CD11c(low)/B220(+)/PDCA-1(+) plasmacytoid dendritic cells (pDCs). Lag3 expression, as determined by real time PCR, was approximately 10-fold greater in pDCs than in either regulatory T cells or activated T effector cells. Activated pDCs also generate approximately 5 times more sLAG-3 than activated T cells. LAG-3-deficient pDCs proliferate and expand more than wild-type pDCs in vivo in response to the TLR9 ligand, CpG. However, the effect of LAG-3 appears to be selective as there was no effect of LAG-3 on the expression of MHC class II, TLR9, and chemokine receptors, or on cytokine production. Lastly, adoptive transfer of either Lag3(+/+) or Lag3(-/-) T cells plus or minus Lag3(+/+) or Lag3(-/-) pDCs defined a role for LAG-3 in controlling pDC homeostasis as well as highlighting the consequences of deregulated Lag3(-/-) pDCs on T cell homeostasis. This raised the possibility of homeostatic reciprocity between T cells and pDCs. Collectively, our data suggests that LAG-3 plays an important but selective cell intrinsic and cell extrinsic role in pDC biology, and may serve as a key functional marker for their study.
Figures




Similar articles
-
Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3.J Invest Dermatol. 2014 Jul;134(7):1893-1902. doi: 10.1038/jid.2014.29. Epub 2014 Jan 17. J Invest Dermatol. 2014. PMID: 24441096
-
Murine plasmacytoid pre-dendritic cells generated from Flt3 ligand-supplemented bone marrow cultures are immature APCs.J Immunol. 2002 Dec 15;169(12):6711-9. doi: 10.4049/jimmunol.169.12.6711. J Immunol. 2002. PMID: 12471102
-
Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223).J Immunol. 2005 Jan 15;174(2):688-95. doi: 10.4049/jimmunol.174.2.688. J Immunol. 2005. PMID: 15634887
-
LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination.Trends Immunol. 2003 Dec;24(12):619-22. doi: 10.1016/j.it.2003.10.001. Trends Immunol. 2003. PMID: 14644131 Review.
-
The CD4-like molecule LAG-3, biology and therapeutic applications.Expert Opin Ther Targets. 2011 Jan;15(1):91-101. doi: 10.1517/14712598.2011.540563. Expert Opin Ther Targets. 2011. PMID: 21142803 Review.
Cited by
-
Immune checkpoint blockade: a common denominator approach to cancer therapy.Cancer Cell. 2015 Apr 13;27(4):450-61. doi: 10.1016/j.ccell.2015.03.001. Epub 2015 Apr 6. Cancer Cell. 2015. PMID: 25858804 Free PMC article. Review.
-
Progress of immune checkpoint LAG-3 in immunotherapy.Oncol Lett. 2020 Nov;20(5):207. doi: 10.3892/ol.2020.12070. Epub 2020 Sep 8. Oncol Lett. 2020. PMID: 32963613 Free PMC article. Review.
-
LAG-3 Confers a Competitive Disadvantage upon Antiviral CD8+ T Cell Responses.J Immunol. 2016 Jul 1;197(1):119-27. doi: 10.4049/jimmunol.1401594. Epub 2016 May 20. J Immunol. 2016. PMID: 27206765 Free PMC article.
-
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding.Sci Immunol. 2020 Jul 17;5(49):eabc2728. doi: 10.1126/sciimmunol.abc2728. Sci Immunol. 2020. PMID: 32680952 Free PMC article.
-
LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance.Front Oncol. 2022 Apr 14;12:831407. doi: 10.3389/fonc.2022.831407. eCollection 2022. Front Oncol. 2022. PMID: 35494015 Free PMC article. Review.
References
-
- Workman CJ, Dugger KJ, Vignali DA. Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J Immunol. 2002;169:5392–5395. - PubMed
-
- Workman CJ, Vignali DAA. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol. 2003;33:970–979. - PubMed
-
- Workman CJ, Cauley LS, Kim IJ, Blackman MA, Woodland DL, Vignali DA. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol. 2004;172:5450–5455. - PubMed
-
- Workman CJ, Vignali DA. Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223) J Immunol. 2005;174:688–695. - PubMed
-
- Hannier S, Tournier M, Bismuth G, Triebel F. CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. J Immunol. 1998;161:4058–4065. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI039480/AI/NIAID NIH HHS/United States
- AI39480/AI/NIAID NIH HHS/United States
- P30 CA021765-30/CA/NCI NIH HHS/United States
- CA-21765/CA/NCI NIH HHS/United States
- R29 AI039480/AI/NIAID NIH HHS/United States
- R01 AI058156/AI/NIAID NIH HHS/United States
- AI058156/AI/NIAID NIH HHS/United States
- AI62921/AI/NIAID NIH HHS/United States
- P30 CA021765/CA/NCI NIH HHS/United States
- R01 AI062921/AI/NIAID NIH HHS/United States
- R01 AI058156-05/AI/NIAID NIH HHS/United States
- R01 AI039480-12/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials